written on 02.06.2014
pt:
Tags:
,

J&J's Imbruvica thumps GSK's Arzerra in head-to-head leukemia trial

TAGS: ,

Results are in from a showdown between chronic lymphocytic leukemia drugs Imbruvica, from Johnson & Johnson's Janssen unit, and GlaxoSmithKline's Arzerra. And as it turns out, it wasn't much of a contest.

Latest Report